Gelatinase expression in retinoblastoma: Modulation of LHBETATAG retinal tumor development by anecortave acetate

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 6, 2010, Pages 2860-2864

  Livia Bajenaru, M ^a   Piña, Yolanda ^a   Murray, Timothy G ^a   Cebulla, Colleen M ^b   Feuer, William ^a   Jockovich, Maria Elena ^a   Castaño, Aria Encarna Marin ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; GELATINASE A; GELATINASE B; ANGIOGENESIS INHIBITOR; PREGNANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; SINGLE DRUG DOSE; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; ZYMOGRAPHY; ANIMAL; DISEASE MODEL; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; RETINA TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; PREGNADIENEDIOLS; RETINAL NEOPLASMS; RETINOBLASTOMA; UP-REGULATION;

EID: 77953257903     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4500     Document Type: Article

References (33)

1. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990; 108:128-132.
2. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122:1316-1323.
3. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206-1213.
4. Rouic LL, Aerts I, Levy-Gabriel C, et al. Conservative treatments of intraocular retinoblastoma. Ophthalmology. In press.
5. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85:1121-1128.
6. Scott IU, Murray TG, Feuer WJ, et al. External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol. 1999;117:766-770.
7. Chan HS, Gallie BL, Munier FL, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. 2005;18:55-63, 8.
8. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118:577-578.
9. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006;47:1264-1268.
10. Escalona-Benz E, Jockovich ME, Murray TG, et al. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2005;46:8-11.
11. Tell S, Yi H, Jockovich ME, Murray TG, Hackam AS. The Wnt signaling pathway has tumor suppressor properties in retinoblastoma. Biochem Biophys Res Commun. 2006;349:261-269.
12. Jockovich ME, Bajenaru ML, Pina Y, et al. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH (BETA) T (AG) mouse model. Invest Ophthalmol Vis Sci. 2007;48: 2476-2482.
13. Boutrid H, Jockovich ME, Murray TG, et al. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:2799-2805
14. Albert DM, Tapper D, Robinson NL, Felman R. Retinoblastoma and angiogenesis activity. Retina. 1984;4:189-194.
15. Tapper D, Langer R, Bellows AR, Folkman J. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery. 1979;86: 36-40.
16. Walton DS, Grant WM. Retinoblastoma and iris neovascularization. Am J Ophthalmol. 1968;65:598-599.
17. Marback EF, Arias VE, Paranhos A Jr, Soares FA, Murphree AL, Erwenne CM. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol. 2003; 87:1224-1228.
18. Kerimogglu H, Kiratli H, Dincturk AA, Soylemezoglu F, Bilgic S. Quantitative analysis of proliferation, apoptosis, and angiogenesis in retinoblastoma and their association with the clinicopathologic parameters. Jpn J Ophthalmol. 2003;47:565-571.
19. Rossler J, Dietrich T, Pavlakovic H, et al. Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol. 2004;164:391-394.
20. Conway RM, Wheeler SM, Murray TG, Jockovich ME, O'Brien JM. Retinoblastoma: animal models. Ophthalmol Clin North Am. 2005;18:25-39, 7.
21. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001;42:283-290.
22. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
23. Ho TY, Yan W, Bagnell CA. Relaxin-induced matrix metalloproteinase- 9 expression is associated with activation of the NF+B pathway in human THP-1 cells. J Leukoc Biol. 2007;81:1303-1310.
24. Yoo YA, Kang MH, Kim JS, Oh SC. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis. 2008;29:480-490.
25. Marin-Castano ME, Striker GE, Alcazar O, Catanuto P, Espinosa-Heidmann DG, Cousins SW. Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci. 2006;47:4098-4112.
26. Otsuka K, Ohshima M, Kaku M, et al. An improved assay method for fibroblast gelatinolytic enzyme. J Nihon Univer Sch Dent. 1997;39:182-190.
27. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metast Rev. 2006;25:9-34.
28. Adithi M, Nalini V, Kandalam M, Krishnakumar S. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma. J Pediatr Hematol Oncol. 2007;29:399-405.
29. Gossage JA, Humphries J, Modarai B, Burnand KG, Smith A. Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution. J Vasc Surg. 2006;44:1085-1090.
30. de Franceschi L, Malpeli G, Scarpa A, et al. Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. Am J Physiol. 2006;291: L457-L465.
31. Clark AF, Mellon J, Li XY, et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci. 1999;40:2158-2162.
32. Pina Y, Boutrid H, Schefler A, et al. Blood vessel maturation in human and LHBETATAG mouse model retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci. 2009;50:1020-1024.
33. Jockovich ME, Suarez F, Alegret A, et al. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model. Invest Ophthalmol Vis Sci. 2007;48:5371-5376.